NCCN guidelinesĀ® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines Article Report uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Lung Neoplasms
  • Lymphoma, Large-Cell, Anaplastic

abstract

  • These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

authors

publication date

  • March 2016

Research

keywords

  • Report

Identity

PubMed ID

  • 26957612

Additional Document Info

start page

  • 255

end page

  • 64

volume

  • 14

number

  • 3